99$/KG
89$/KG
Product Detailed Description
liposomal L-carnitine 70% is a premium-grade dietary supplement ingredient delivering L-carnitine in an advanced liposomal delivery system. L-Carnitine (CAS 541-15-1), also known as levocarnitine, (R)-carnitine, or (R)-(3-carboxy-2-hydroxypropyl)trimethylammonium inner salt, is a water-soluble quaternary amine with the molecular formula C₇H₁₅NO₃ and a molecular weight of 161.20 g/mol. It occurs as a white crystalline, hygroscopic powder that is freely soluble in water and warm alcohol, and practically insoluble in acetone. The compound is optically active with a specific rotation between −29° and −32°.
L-Carnitine is a conditionally essential nutrient that plays a critical role in mitochondrial Energy Metabolism. Its principal function is the transfer of long-chain fatty acids from the cytosol into the mitochondrial matrix for β-oxidation, where they are broken down to generate acetyl-CoA and ATP. Approximately 95% of the body‘s total carnitine stores are found in skeletal and cardiac muscle, where energy demand is highest. L-Carnitine is also thought to be necessary as an acyl group acceptor to maintain sufficient levels of free coenzyme A (CoA) in the cell, and it may operate as an osmoprotectant in sensitive organs such as the kidney.
Conventional L-carnitine presents significant bioavailability challenges. Following oral administration, L-carnitine absorption is mediated by the organic cation transporter 2 (OCTN2), which is saturable and exhibits dose-dependent absorption kinetics. The oral bioavailability of L-carnitine is only 14–18%, with a short half-life of 30–60 minutes and an inability to be stored in the body, requiring frequent dosing for effective treatment. These limitations reduce patient compliance and therapeutic efficacy, particularly for chronic conditions requiring sustained carnitine supplementation.
Liposomal encapsulation provides four critical advantages:
1. Dramatically Enhanced Blood Retention and Pharmacokinetics — A pharmacokinetic study in rats compared intravenous administration of free ³H-L-carnitine versus liposome-encapsulated L-carnitine. The retention of carnitine in liposomes in the blood system was significantly higher—up to 300% compared to standard administration. The distribution half-life (t1/2α) increased by 154% to 0.68 hours, and the terminal half-life (t1/2β) increased by 140% to 7.94 hours, while total clearance decreased by 400% compared to standard carnitine administration.
2. Targeted Organ Accumulation — The liposomal formulation accumulated to a higher extent in the liver (156%) and spleen (336%), while concentrations in the lungs (52%), heart (55%), and muscle tissue (54%) decreased markedly relative to the standard formulation. This organ distribution profile is particularly advantageous for addressing hepatic carnitine deficiency and for conditions involving the liver and spleen.
3. Sustained Release for Prolonged Metabolic Support — In vitro release studies comparing free L-carnitine solution with liposomal formulations demonstrated that the free solution released 90% of its content within the first hour, whereas the liposomal formulation maintained a controlled-release profile for 12 hours. This sustained-release profile supports prolonged carnitine availability for mitochondrial fatty acid oxidation.
4. Enhanced Stability and Protection — The novel liposomal dosage form of L-carnitine is stable both in vitro (t1/2 at 4°C = 187 days) and in vivo, and may be successfully used in the therapy of carnitine deficiency, for instance in patients with renal failure or liver disease. The phospholipid bilayer shields L-carnitine from premature degradation during digestive transit.
High Purity — Standardized to ≥70% L-carnitine in the liposomal formulation, with USP/EP-grade assay of 97.0%–103.0% on anhydrous basis available for pharmaceutical applications.
Liposomal Enhancement — Liposome encapsulation increases blood retention by up to 300%, extends the terminal half-life from 3.3 to 7.94 hours (+140%), and reduces total clearance by 400% compared to free L-carnitine.
Targeted Organ Delivery — Liposomal L-carnitine accumulates to a higher extent in the liver (156%) and spleen (336%), providing targeted delivery for hepatic and splenic applications.
Sustained Release — Liposomal formulation maintains a controlled-release profile for 12 hours, compared to 90% release within 1 hour for free L-carnitine.
Clinically Validated for Glycemic Control — A 2023 meta-analysis of 41 randomized clinical trials demonstrated that L-carnitine supplementation at 0.25–4 g/day for 2–52 weeks reduced fasting blood glucose, insulin resistance, and glycosylated hemoglobin (HbA1c) in patients with metabolic disorders.
Fatty Acid Oxidation and Energy Metabolism — L-Carnitine is the essential carrier for long-chain fatty acids into the mitochondrial matrix for β-oxidation, supporting ATP generation in cardiac and skeletal muscle.
Athletic Performance and Recovery — L-Carnitine supplementation has been shown to support weight loss, improve physical performance during intensive exercise, and enhance recovery.
Antioxidant and Anti-Aging Support — L-Carnitine acts as an antioxidant, protecting key enzymes contributing to the body‘s antioxidant defense system from peroxidative damage, and is effective in regulating age-related changes.
Water-Dispersible — Liposomal powder offers excellent dispersibility in aqueous systems; suitable for capsules, tablets, powder drink mixes, and functional beverages.
Batch Traceability — Complete COA, HPLC chromatogram, and identity data provided for each batch.
Clinical studies and commercial products commonly recommend varying doses of L-carnitine depending on the application. For general supplementation, the typical dosage is 1,000–3,000 mg per day, divided into multiple doses. A 2023 meta-analysis of 41 randomized clinical trials demonstrated that L-carnitine supplementation at 0.25–4 g/day for 2–52 weeks reduced fasting blood glucose, insulin resistance, and HbA1c, with subgroup analyses indicating stronger effects at higher doses (≥2,000 mg/day) and longer durations (≥12 weeks). For therapeutic carnitine deficiency, the recommended dosage is 50–100 mg/kg/day divided into 2–4 doses daily, with dose adjustment for children (75–100 mg/kg/day) and adults (50–75 mg/kg/day). For athletic performance, a standard protocol of 2 g taken 60 minutes before exercise, or an experimental protocol of 1 g taken 90 and 60 minutes before exercise, has been used. Liposomal formulations may allow for more efficient utilization of lower doses due to enhanced bioavailability and sustained release.
Important Safety Information: L-Carnitine is generally well tolerated. Chronic administration of high doses of oral L-carnitine may lead to accumulation of potentially toxic metabolites such as trimethylamine and trimethylamine-N-oxide in patients with severe or end-stage renal impairment, and high oral doses should not be administered for prolonged periods in these patients. In diabetic patients treated with insulin and/or oral hypoglycemic agents, L-carnitine administration may cause hypoglycemia, and regular monitoring of plasma glucose levels is recommended. Cases of increased international normalized ratio (INR) have been reported in patients concomitantly treated with warfarin. Pregnant or lactating women and children should consult a healthcare professional before use.
Stock Orders: 3–5 business days after payment confirmation.
Bulk / Custom Orders: 2–3 weeks, depending on quantity and customization requirements.
Shipping Methods: International Express (FedEx, DHL, UPS), air freight, and sea freight.
Coverage: Worldwide shipping, including remote areas.
99$/KG
89$/KG
이 웹사이트는 귀하가 당사 웹사이트에서 최상의 경험을 할 수 있도록 쿠키를 사용합니다.
English
Español
Français
Deutsch
日本語
핸드폰
논평
（0）